作者
Mohammad Bosaeed, Ebrahim Mahmoud, Ahmad Alharbi, Hadeel Altayib, Hawra Albayat, Faisal Alharbi, Khalid Ghalilah, Abdulmajid Al Arfaj, Jumana AlJishi, Abdullatif Alarfaj, Hajar Alqahtani, Badriah M Almutairi, Manar Almaghaslah, Nawaf M Alyahya, Abdullah Bawazir, Saud AlEisa, Abdulrahman Alsaedy, Abderrezak Bouchama, Malak Alharbi, Majid AlShamrani, Sameera Al Johani, Majed Aljeraisy, Mohammed Alzahrani, Abdulhakeem O Althaqafi, Hassan Almarhabi, Athari Alotaibi, Nasser Alqahtani, Yaseen M Arabi, Omar S Aldibasi, Ahmad Alaskar
发表日期
2021/12
期刊
Infectious Diseases and Therapy
卷号
10
页码范围
2291-2307
出版商
Springer Healthcare
简介
Introduction
Antiviral drugs have shown limited effectiveness in treating patients with coronavirus disease 2019 (COVID-19). We aimed to assess the effects of a favipiravir and hydroxychloroquine combination on treating moderate-to-severe COVID-19 patients.
Methods
An investigator-initiated, multicenter, open-label, randomized trial at nine hospitals. Eligible patients were adults with moderate-to-severe COVID-19 defined as oxygen saturation (SaO2) of ≤ 94% while breathing ambient air or significant clinical symptoms with chest x-ray changes requiring hospital admission. Randomization was in a 1:1 ratio to receive standard care (control group) or standard care plus favipiravir and hydroxychloroquine. The primary outcome was time to clinical improvement of two points (from the status at randomization) on a seven-category ordinal scale or live …
学术搜索中的文章
M Bosaeed, E Mahmoud, A Alharbi, H Altayib… - Infectious Diseases and Therapy, 2021